High Hematocrit on TRT: Thresholds, Causes and What Doctors Do
Hematocrit is the lab value most likely to change a TRT protocol. This guide covers where the guidelines draw the line, why short-acting injections push it harder than gels, and the order in which prescribers usually respond, from dose changes to phlebotomy.
- The Endocrine Society treats a hematocrit above 54% on therapy as erythrocytosis: stop testosterone until it falls to a safe level, check for hypoxia and sleep apnea, then restart at a lower dose. The AUA uses 54% on therapy and 50% before starting.
- The rise depends on dose, is larger in older men, and is usually largest with short-acting intramuscular injections. Gels and long-acting formulations raise it less.
- Hematocrit is checked at baseline, 3–6 months after starting, and then once a year. Most of the rise happens within the first few months.
- Therapeutic phlebotomy brings the number down, but no study has shown that it prevents clots. A 2024 review recommends adjusting the dose and treating risk factors first. Donating blood through a blood center is not the same as a prescribed phlebotomy.
On TRT, hematocrit is too high once it goes above 54%. That is the cutoff the Endocrine Society uses for erythrocytosis, and it tells prescribers to stop testosterone until the value drops to a safe level, look for hypoxia and sleep apnea, and then restart at a lower dose1. The American Urological Association (AUA) also acts at 54% during treatment, with a dose reduction or a temporary pause, and it recommends holding off on starting TRT at all if baseline hematocrit is over 50% until the cause is known2. This guide looks only at that one marker: why testosterone raises it, which formulations raise it most, how much risk it carries, and what prescribers do about it. The full lab panel and draw timing are covered in the TRT bloodwork guide.
What counts as high: the guideline thresholds
Hematocrit is the share of your blood volume taken up by red blood cells. Guidelines set one line for starting therapy and a second line for men already on it. The baseline line is stricter because a man who starts near the top of the range has little room before he crosses the treatment threshold.
| Source | Before starting TRT | During TRT | Recommended response |
|---|---|---|---|
| Endocrine Society (2018) | Above the lab's upper limit of normal: do not start without discussing erythrocytosis risk and close monitoring. Above 48% (above 50% at high altitude) is listed as a moderate-to-high-risk condition1 | Above 54%1 | Stop until hematocrit falls to a safe level; check for hypoxia and sleep apnea; restart at a lower dose1 |
| AUA (2018) | Above 50%: consider holding off on therapy until the cause is investigated2 | 54%2 | Dose reduction or temporary discontinuation2 |
| FDA label, testosterone cypionate | — | No number given | Check hemoglobin and hematocrit periodically during long-term use "to detect polycythemia"11 |
Other societies draw the line in slightly different places. A 2024 review in Endocrine Connections summarizes European and British guidance: the British Society for Sexual Medicine wants hematocrit kept below 54%, the European Academy of Andrology calls for stopping TRT above 54%, and the European Association of Urology lists dose reduction, a change of formulation, or a 500 mL venesection when levels are very high8. In the guidelines above, the action points sit at 54% on therapy; values between 50% and 54% are not an action threshold in themselves, but they leave little margin.
Why testosterone raises hematocrit
Testosterone acts on red cell production in two ways. In a trial of older men given testosterone gel for six months, erythropoietin (EPO), the kidney hormone that drives red cell production, rose 58% within the first month. Over the same period hepcidin, which restricts how much iron the marrow can use, fell by roughly half. Hemoglobin rose about 7% and hematocrit about 10% (around 4.4 percentage points). The rise peaked by month three and held through month six4. EPO later drifted back toward baseline while hematocrit stayed high, which the authors read as testosterone resetting the body's EPO-to-hemoglobin set point4.
The effect depends on dose. In a trial that gave young and older men fixed weekly doses from 25 to 600 mg for 20 weeks, hemoglobin and hematocrit rose in a straight line with dose. The rise was larger in older men at every dose3. The Endocrine Society guideline says the same: the rise tracks testosterone dose and blood levels, erythrocytosis is more common in older men, and it is the most frequent adverse event reported in randomized trials of testosterone1.
When hematocrit rises, and when to check it
The Endocrine Society schedule is hematocrit at baseline, again 3–6 months after starting, and then once a year1. That timing matches how the rise behaves: in the gel trial above it was largely complete by three months4. It can also keep climbing for longer. A review of erythrocytosis on TRT reports that the average time to cross 50% was about 10.5 months on injections, 14 months on gels and 16.4 months on pellets, with wide variation between men5. So one normal result at three months doesn't settle the question. Checking once a year after that is what catches a slow climb.
When to draw matters less for hematocrit than for testosterone, but a recheck after any dose or protocol change still makes sense. A new dose produces a new steady state, and a hematocrit measured on the old protocol won't reflect it. The bloodwork guide explains how to time the testosterone draw on the same visit.
Formulation, route and dose: which protocols raise it most
The AUA guideline notes that injectable testosterone has been linked to the largest treatment-induced increases in hemoglobin and hematocrit2. The Endocrine Society lists "less erythrocytosis than injectable T" as an advantage of transdermal gels1. The explanation usually given is peak level: a short-acting cypionate or enanthate injection pushes testosterone into the supraphysiologic range within days, then lets it fall back over the following one to two weeks5.
| Formulation | What published data show |
|---|---|
| Short-acting IM injection (cypionate, enanthate) | 66.7% of men went above 50% hematocrit in one comparison summarized in a review of TRT erythrocytosis5 |
| Testosterone pellets | 35.1% above 50% in the same review's summary5 |
| Transdermal gel | 12.8% above 50%5; gel dose mattered, with erythrocytosis rising from 11.3% to 17.9% when the dose was doubled from 50 to 100 mg/day5 |
| Long-acting IM testosterone undecanoate | 7% above 50%5 |
| SC enanthate autoinjector vs IM cypionate | In 263 men, the subcutaneous autoinjector was independently linked to lower post-treatment hematocrit and estradiol6 |
The table mixes study populations and definitions, so read it as a ranking rather than as rates you can compare line by line. The 2024 review notes that direct head-to-head trials of formulations are "largely lacking"8. The same point applies to injection frequency. Splitting a weekly dose into smaller, more frequent injections lowers the peak, and that is the logic behind TRT microdosing and subcutaneous protocols. Trials that isolate frequency as the only variable affecting hematocrit are scarce, though. In practice frequency is one lever a prescriber may try, and a recheck shows whether it worked for you.
How dangerous is high hematocrit on TRT?
The evidence is mixed. In one large dataset, a matched analysis drawn from a database of 74 million patients, men who developed a hematocrit of 52% or higher during their first year of TRT had a higher rate of major adverse cardiovascular events or venous thromboembolism than matched men who didn't: 5.15% versus 3.87% (odds ratio 1.35). At a 50% cutoff the difference disappeared7. The Endocrine Society guideline, though, says the hematocrit level at which clotting or cardiovascular risk starts to rise is not known, and that neuro-occlusive events in trial participants who developed erythrocytosis have been very rare1. The FDA label for testosterone cypionate lists postmarketing reports of deep vein thrombosis and pulmonary embolism11.
What prescribers typically do
The steps below reflect the guideline wording and the 2024 review. Your prescriber may reorder them depending on how high the value is, how fast it climbed, and your cardiovascular risk.
- Look for a second cause. The Endocrine Society asks for an evaluation for hypoxia and sleep apnea when hematocrit goes above 54%. The 2024 review adds smoking and severe obstructive sleep apnea as risk factors to address before anything else.
- Lower the dose. Because the effect tracks dose, a lower dose is the most direct lever. The Endocrine Society's instruction is to restart at a reduced dose once hematocrit has recovered.
- Change frequency or formulation. A review of TRT erythrocytosis suggests transdermal or subcutaneous options for men at risk, since short-acting IM peaks are the usual explanation for the larger rise.
- Pause therapy. Both the Endocrine Society and the AUA allow a temporary stop until hematocrit returns to the normal range. After testosterone is stopped, hemoglobin and hematocrit have been reported to return to baseline within 3–12 months.
- Therapeutic phlebotomy. The Endocrine Society calls it effective at lowering hematocrit. The 2024 review points out that there is no evidence it improves outcomes, and argues that repeated phlebotomy lowers iron stores and could, in theory, raise clotting risk through hypoxia-signaling pathways. It recommends shared decision-making and trying dose changes first.
Sources for the steps above: the Endocrine Society guideline1, the AUA guideline2, the erythrocytosis review by Ohlander and colleagues5, and the 2024 phlebotomy review8. The iron point matters because the lab value can look fixed while stores run down. A man whose hematocrit is kept in range by frequent draws may be iron-depleted. That is one reason the review treats phlebotomy as a last step rather than a routine one8.
Blood donation vs therapeutic phlebotomy
Some men handle rising hematocrit by donating blood, and some blood centers accept TRT patients as donors. One U.S. regional blood center, Carter BloodCare, says testosterone therapy is not a reason to be ineligible. Blood from these donors can be used for transfusion if the donor meets the standard criteria, and draws more often than every eight weeks require the physician to submit a phlebotomy prescription form10. Policies differ between blood centers, so check with yours before relying on it.
Donation doesn't always keep up. At a Canadian blood donation clinic, 39 men on TRT had a mean hemoglobin of 173 g/L, readings of 180 g/L or more came up at a quarter of their appointments, and 44% of repeat donors stayed persistently elevated. The authors concluded that routine donation alone was not enough to control TRT-induced polycythemia9. If your number keeps rising despite donating, it is time to talk to your prescriber about the dose, not to donate more often.
Sleep apnea, smoking and altitude
Low oxygen levels drive red cell production on their own, which is why guidelines single out conditions that cause them. The Endocrine Society recommends against starting testosterone in men with untreated severe obstructive sleep apnea, lists new or worsening sleep apnea as an uncommon adverse event of TRT, and includes sleep apnea in the workup when hematocrit goes above 54%1. It also gives men living at high altitude a slightly higher baseline allowance (50% instead of 48%)1. The 2024 review names smoking and severe sleep apnea as the modifiable risk factors to treat before considering phlebotomy8. If your hematocrit climbs faster than your dose would explain, ask whether one of these could be adding to it.
Tracking the trend, not just the number
One hematocrit result tells you little without context. A reading of 51% means something different if you started at 42% than if you started at 49%, and a steady climb over three draws is a clearer signal than a single high value. Log each result together with the dose, formulation and injection frequency you were on when it was drawn. That record makes a dose-change conversation with your prescriber concrete. Peptide Me lets you log bloodwork next to your injection history and chart hematocrit over time, and the TRT dose calculator helps you see what a proposed dose change means in mg and mL. For the rest of the monitoring panel, see the TRT bloodwork guide, the estradiol on TRT guide, the TRT results timeline and the TRT hub.
Disclaimer: this article summarizes published guidelines and studies on hematocrit during testosterone therapy. It is not medical advice. Testosterone is a prescription, controlled medication. Whether a given hematocrit calls for a dose change, a pause or phlebotomy depends on your history and risk factors, and that decision belongs to the clinician managing your treatment. If you have symptoms such as chest pain, shortness of breath, one-sided leg swelling, or sudden weakness or vision change, seek urgent care rather than waiting for a lab result.
FAQ
References
Primary sources — PubMed / NEJM / The Lancet.
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://academic.oup.com/jcem/article/103/5/1715/4939465
- Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. https://www.auanet.org/documents/Guidelines/PDF/Testosterone-Deficiency-JU.pdf
- Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93(3):914-919. https://pubmed.ncbi.nlm.nih.gov/18160461/
- Bachman E, Travison TG, Basaria S, et al. Testosterone Induces Erythrocytosis via Increased Erythropoietin and Suppressed Hepcidin: Evidence for a New Erythropoietin/Hemoglobin Set Point. J Gerontol A Biol Sci Med Sci. 2014;69(6):725-735. https://pmc.ncbi.nlm.nih.gov/articles/PMC4022090/
- Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis Following Testosterone Therapy. Sex Med Rev. 2018;6(1):77-85. https://pmc.ncbi.nlm.nih.gov/articles/PMC5690890/
- Choi EJ, Xu P, Barham D, El-Khatib FM, Yafi FA, Kavoussi PK. Comparison of Outcomes for Hypogonadal Men Treated with Intramuscular Testosterone Cypionate versus Subcutaneous Testosterone Enanthate. J Urol. 2022;207(3):677-683. https://pubmed.ncbi.nlm.nih.gov/34694927/
- Ory J, Nackeeran S, Balaji NC, Hare JM, Ramasamy R. Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy. J Urol. 2022;207(6):1295-1301. https://pmc.ncbi.nlm.nih.gov/articles/PMC12721636/
- Bond P, Verdegaal T, Smit DL. Testosterone therapy-induced erythrocytosis: can phlebotomy be justified? Endocr Connect. 2024;13(10):e240283. https://pmc.ncbi.nlm.nih.gov/articles/PMC11466264/
- Chin-Yee B, Lazo-Langner A, Butler-Foster T, Hsia C, Chin-Yee I. Blood donation and testosterone replacement therapy. Transfusion. 2017;57(3):578-581. https://pubmed.ncbi.nlm.nih.gov/28150363/
- Carter BloodCare. Testosterone Therapy (donor education page). https://www.carterbloodcare.org/education-center/types-of-donations/testosterone-therapy/
- DailyMed. DEPO-TESTOSTERONE (testosterone cypionate) injection, solution — Prescribing Information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cfbb53d4-b868-4a28-8436-f9112eb01c39